Correlation Between Editas Medicine and Royalty Pharma

Can any of the company-specific risk be diversified away by investing in both Editas Medicine and Royalty Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Editas Medicine and Royalty Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Editas Medicine and Royalty Pharma Plc, you can compare the effects of market volatilities on Editas Medicine and Royalty Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Editas Medicine with a short position of Royalty Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Editas Medicine and Royalty Pharma.

Diversification Opportunities for Editas Medicine and Royalty Pharma

0.84

Correlation Coefficient

Editas Medicine  Royalty Pharma

Very poor diversification

The 3 months correlation between Editas and Royalty is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Editas Medicine and Royalty Pharma Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Pharma Plc and Editas Medicine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Editas Medicine are associated (or correlated) with Royalty Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Pharma Plc has no effect on the direction of Editas Medicine i.e., Editas Medicine and Royalty Pharma go up and down completely randomly.

Pair Corralation between Editas Medicine and Royalty Pharma

Given the investment horizon of 90 days Editas Medicine is expected to under-perform the Royalty Pharma. In addition to that, Editas Medicine is 3.32 times more volatile than Royalty Pharma Plc. It trades about -0.08 of its total potential returns per unit of risk. Royalty Pharma Plc is currently generating about -0.04 per unit of volatility. If you would invest  3,316  in Royalty Pharma Plc on September 25, 2024 and sell it today you would lose (824.00) from holding Royalty Pharma Plc or give up 24.85% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	99.76%
Values	Daily Returns

Editas Medicine  vs.  Royalty Pharma Plc

Editas Medicine

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Royalty Pharma Plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Royalty Pharma Plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Editas Medicine and Royalty Pharma

The main advantage of trading using opposite Editas Medicine and Royalty Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Editas Medicine position performs unexpectedly, Royalty Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will offset losses from the drop in Royalty Pharma's long position.

The idea behind Editas Medicine and Royalty Pharma Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.